Overall, these results highlight the importance of the JAK-STAT pathway in P. falciparum-mediated barrier disruption and support the therapeutic potential of Ruxolitinib in reducing brain vascular dysfunction associated with cerebral malaria. Here, SOAT1 is linked to cerebral malaria.